Spectral Medical (TSE:EDT) has released an update. Spectral Medical has successfully enrolled 135 patients in its Phase 3 Tigris trial, which ...

Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Despite a lower enrollment rate for October we continue to see strong performance across trial sites for screening. Our sites are eager to ...

DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ...